The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study
Introduction. Sentinel lymph node biopsy in prophylactic mastectomy is controversial. It avoids lymphadenectomy in occult carcinoma but is associated with increased morbidity. Women with BRCA mutations have a higher incidence of occult carcinoma and our objective was to assess the clinical utility o...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2018/1426369 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235592070135808 |
|---|---|
| author | Sara Câmara Daniela Pereira Saudade André Beatriz Mira Fátima Vaz Rodrigo Oom José Carlos Marques João Leal de Faria Catarina Rodrigues dos Santos |
| author_facet | Sara Câmara Daniela Pereira Saudade André Beatriz Mira Fátima Vaz Rodrigo Oom José Carlos Marques João Leal de Faria Catarina Rodrigues dos Santos |
| author_sort | Sara Câmara |
| collection | DOAJ |
| description | Introduction. Sentinel lymph node biopsy in prophylactic mastectomy is controversial. It avoids lymphadenectomy in occult carcinoma but is associated with increased morbidity. Women with BRCA mutations have a higher incidence of occult carcinoma and our objective was to assess the clinical utility of sentinel lymph node biopsy when these women undergo prophylactic mastectomy. Materials and Methods. Seven-year retrospective consecutive case-series study of women, with a BRCA deleterious mutation, admitted to prophylactic mastectomy, at our center. Breast MRI < 6 months before surgery was routine, unless contraindicated. Results. Fifty-seven patients (43% BRCA1; 57% BRCA2) underwent 80 prophylactic mastectomies. 72% of patients had had breast cancer treated before prophylactic mastectomy or synchronously to it. The occult carcinoma incidence was 5%, and half of the cases were invasive. SLNB was performed in 19% of the prophylactic mastectomies; none of these had tumor invasion. Women with invasive carcinoma who had not undergone sentinel lymph node biopsy were followed closely with axillary ultrasound. The median follow-up was 37 months, with no local recurrence; 1 patient died of primary tumor systemic relapse. Conclusions. Our data do not support this procedure for routine (in agreement with previous literature), in this high risk for occult carcinoma population. |
| format | Article |
| id | doaj-art-12524336ba2d4deb926bdbd5f1bd910e |
| institution | OA Journals |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-12524336ba2d4deb926bdbd5f1bd910e2025-08-20T02:02:12ZengWileyInternational Journal of Breast Cancer2090-31702090-31892018-01-01201810.1155/2018/14263691426369The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series StudySara Câmara0Daniela Pereira1Saudade André2Beatriz Mira3Fátima Vaz4Rodrigo Oom5José Carlos Marques6João Leal de Faria7Catarina Rodrigues dos Santos8Department of Gynecology and Obstetrics, Hospital Dr. Nélio Mendonça, Avenida Luís de Camões, No. 57, 9004-514 Funchal, PortugalDepartment of Pathology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalDepartment of Pathology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalDepartment of Breast Cancer Risk Evaluation Clinic and Department of Medical Oncology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalDepartment of Breast Cancer Risk Evaluation Clinic and Department of Medical Oncology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalDepartment of Surgical Oncology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalRadiology Department, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalDepartment of Surgical Oncology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalDepartment of Surgical Oncology, Instituto Português de Oncologia Francisco Gentil (IPOLFG), Lisbon, PortugalIntroduction. Sentinel lymph node biopsy in prophylactic mastectomy is controversial. It avoids lymphadenectomy in occult carcinoma but is associated with increased morbidity. Women with BRCA mutations have a higher incidence of occult carcinoma and our objective was to assess the clinical utility of sentinel lymph node biopsy when these women undergo prophylactic mastectomy. Materials and Methods. Seven-year retrospective consecutive case-series study of women, with a BRCA deleterious mutation, admitted to prophylactic mastectomy, at our center. Breast MRI < 6 months before surgery was routine, unless contraindicated. Results. Fifty-seven patients (43% BRCA1; 57% BRCA2) underwent 80 prophylactic mastectomies. 72% of patients had had breast cancer treated before prophylactic mastectomy or synchronously to it. The occult carcinoma incidence was 5%, and half of the cases were invasive. SLNB was performed in 19% of the prophylactic mastectomies; none of these had tumor invasion. Women with invasive carcinoma who had not undergone sentinel lymph node biopsy were followed closely with axillary ultrasound. The median follow-up was 37 months, with no local recurrence; 1 patient died of primary tumor systemic relapse. Conclusions. Our data do not support this procedure for routine (in agreement with previous literature), in this high risk for occult carcinoma population.http://dx.doi.org/10.1155/2018/1426369 |
| spellingShingle | Sara Câmara Daniela Pereira Saudade André Beatriz Mira Fátima Vaz Rodrigo Oom José Carlos Marques João Leal de Faria Catarina Rodrigues dos Santos The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study International Journal of Breast Cancer |
| title | The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study |
| title_full | The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study |
| title_fullStr | The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study |
| title_full_unstemmed | The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study |
| title_short | The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study |
| title_sort | use of sentinel lymph node biopsy in brca1 2 mutation carriers undergoing prophylactic mastectomy a retrospective consecutive case series study |
| url | http://dx.doi.org/10.1155/2018/1426369 |
| work_keys_str_mv | AT saracamara theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT danielapereira theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT saudadeandre theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT beatrizmira theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT fatimavaz theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT rodrigooom theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT josecarlosmarques theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT joaolealdefaria theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT catarinarodriguesdossantos theuseofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT saracamara useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT danielapereira useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT saudadeandre useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT beatrizmira useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT fatimavaz useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT rodrigooom useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT josecarlosmarques useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT joaolealdefaria useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy AT catarinarodriguesdossantos useofsentinellymphnodebiopsyinbrca12mutationcarriersundergoingprophylacticmastectomyaretrospectiveconsecutivecaseseriesstudy |